Key Considerations for the Individualizing Use of BTK Inhibitors in B-Cell Malignancies

Experts review guideline recommendations for the use of BTK inhibitors for the management of CLL/SLL and MCL, the selection of BTK inhibitors based on patient characteristics, and key adverse events.

Share

Program Content

Activities

BTK Inhibitors in CLL/SLL and MCL
Key Considerations for the Individualizing Use of BTK Inhibitors in B-Cell Malignancies
Video
Congratulations: You achieved a completion on 04/09/2022

Released: October 11, 2023

Expires: October 10, 2024

View Activity

Activities

BTK Inhibitors in CLL/SLL and MCL
Key Considerations for the Individualizing Use of BTK Inhibitors in B-Cell Malignancies
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: October 11, 2023

View Activity

Faculty

cover img faculity

Matthew S. Davids, MD, MMSc

Director of Clinical Research
Division of Lymphoma
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

cover img faculity

Josie Montegaard, MSN, AGPCNP-BC

Nurse Practitioner
Dana-Farber Cancer Institute
Boston, Massachusetts

Provided by

ProCE Banner

Provided by Partners for Advancing Clinical Education (PACE)

Supporters

Supported by an educational grant from AstraZeneca.

AstraZeneca